Arbidol

DRUG5 trials

Sponsors

Capital Medical University, Shengjing Hospital, Guangzhou 8th People's Hospital, Jieming QU, Zheng Liu

Conditions

2019-nCoVAllergic RhinitisCOPD PatientsCoronavirus InfectionsInfluenza

Phase 3

Severe Influenza Trial of ARbidol

CompletedNCT03787459

Capital Medical UniversityInfluenza

Start: 2019-01-18End: 2024-10-17Updated: 2025-06-25

Phase 4

The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.

CompletedNCT03851991

Shengjing HospitalCOPD Patients

Start: 2019-08-30End: 2024-10-31Updated: 2025-07-20

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

CompletedNCT04252885

Guangzhou 8th People's HospitalCoronavirus Infections

Start: 2020-01-28End: 2020-05-31Updated: 2020-07-01

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

CompletedNCT04260594

Jieming QU2019-nCoV

Start: 2020-02-08End: 2020-12-30Updated: 2021-09-08

Unknown Phase

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

RecruitingNCT06462417

Zheng LiuAllergic Rhinitis

Start: 2024-07-11End: 2025-06-30Target: 15Updated: 2025-05-07

Related Papers

A trial of arbidol hydrochloride in adults with COVID-19

Chinese Medical Journal2022-07-058 citations

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.

2020-05-19213 citations